<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="3-part\PMC7055223\results\search\tropicalVirus\results.xml">
  <result pre="multivalent vaccine candidate against Chikungunya, Japanese Encephalitis, Yellow Fever and" exact="Zika" post="Virus GargHimanshuHimanshu.garg@ttuhsc.eduMehmetoglu-GurbuzTugbaJoshiAnjalianjali.joshi@ttuhsc.edu[], 0000 0001 2179 3554grid.416992.1Center of Emphasis in"/>
  <result pre="an emerging threat as evident from the recent outbreak of" exact="Zika" post="virus (ZIKV) as well as repeated outbreaks of Chikungunya"/>
  <result pre="of Zika virus (ZIKV) as well as repeated outbreaks of" exact="Chikungunya" post="(CHIKV), Yellow fever (YFV) and Japanese encephalitis (JEV) virus"/>
  <result pre="virus (ZIKV) as well as repeated outbreaks of Chikungunya (CHIKV)," exact="Yellow fever" post="(YFV) and Japanese encephalitis (JEV) virus in different geographical"/>
  <result pre="host and vectors for these diseases1,2. Amongst these arboviral diseases," exact="Chikungunya" post="(CHIKV), Japanese Encephalitis (JEV), Yellow Fever (YFV) and Zika"/>
  <result pre="diseases, Chikungunya (CHIKV), Japanese Encephalitis (JEV), Yellow Fever (YFV) and" exact="Zika" post="virus (ZIKV) have expanded from isolated outbreaks in endemic"/>
  <result pre="burden on the healthcare system. The World Health Organization lists" exact="Dengue" post="virus (DENV) as the most common mosquito-borne viral disease"/>
  <result pre="(DENV) as the most common mosquito-borne viral disease with CHIKV," exact="YFV" post="and JEV as other arboviruses being endemic in various"/>
  <result pre="overlapping geographical regions; Aedes sp in the case of CHIKV," exact="YFV" post="and ZIKV and Culex sp in the case of"/>
  <result pre="regions; Aedes sp in the case of CHIKV, YFV and" exact="ZIKV" post="and Culex sp in the case of JEV2. Furthermore,"/>
  <result pre="vulnerable populations. Currently, a live attenuated virus (LAV) vaccine for" exact="YFV" post="and a LAV as well as a killed JEV"/>
  <result pre="including safety and availability. Similarly, a tetravalent LAV vaccine for" exact="Dengue" post="has recently been approved with limited success and much"/>
  <result pre="as vaccines12. Previously, we developed a VLP vaccine candidate for" exact="Zika" post="virus and found that the immunogenicity of Capsid protein"/>
  <result pre="different VLPs in desired concentrations into a single formulation15. The" exact="HPV" post="vaccine is one such example where VLPs from 9"/>
  <result pre="such example where VLPs from 9 closely related strains of" exact="HPV" post="are included to increase antigenic breadth and generate a"/>
  <result pre="to develop a safe and efficacious vaccine targeting CHIKV, JEV," exact="YFV" post="and ZIKV termed (CJaYZ vaccine). Stable cell lines secreting"/>
  <result pre="a safe and efficacious vaccine targeting CHIKV, JEV, YFV and" exact="ZIKV" post="termed (CJaYZ vaccine). Stable cell lines secreting Capsid protein"/>
  <result pre="study demonstrating the effectiveness of Capsid protein containing VLPs for" exact="YFV" post="and JEV as well as the first report demonstrating"/>
  <result pre="arboviruses. Results Synthetic gene constructs expressing structural proteins of YFV," exact="CHIKV" post="and JEV and generation of Capsid protein containing VLPs"/>
  <result pre="structural protein expression vectors for the above viruses. For ZIKV," exact="YFV" post="and JEV it included the CprME genes and for"/>
  <result pre="YFV and JEV it included the CprME genes and for" exact="CHIKV" post="the C-E3-E2-E1 genes. We have previously developed a VLP"/>
  <result pre="genes. We have previously developed a VLP based platform for" exact="Zika" post="Virus using a codon optimized synthetic gene construct13 and"/>
  <result pre="modifications. We developed a consensus sequence for CHIKV, JEV and" exact="YFV" post="to include the most representative circulating virus sequences in"/>
  <result pre="protein expression. As demonstrated in Fig. 1, CHIKV, JEV and" exact="YFV" post="constructs showed E expression upon transfection followed by fluorescence"/>
  <result pre="expression upon transfection followed by fluorescence microscopy. For, JEV and" exact="YFV" post="both E protein and Capsid protein expression was documented"/>
  <result pre="E protein expression could be detected as well (Fig. 1E)." exact="ZIKV" post="protein expression using a similar approach has been characterized"/>
  <result pre="approach has been characterized previously13,14. Figure 1 Characterization of JEV," exact="YFV" post="and CHKV protein expression and VLP release. (A) 293 T"/>
  <result pre="expression vector alone or the JEV CprME vector along with" exact="Zika" post="NS2B-3 expression plasmid. Culture supernatants were ultracentrifuged and analyzed"/>
  <result pre="expression by western blotting. (C) 293 T cells were transfected with" exact="YFV" post="CprME expression vector and analyzed for E protein and"/>
  <result pre="expression by immunofluorescence microscopy. (D) 293 T cells were transfected with" exact="YFV" post="CprME expression vector alone or the YFV CprME vector"/>
  <result pre="were transfected with YFV CprME expression vector alone or the" exact="YFV" post="CprME vector along with Zika NS2B-3 expression plasmid. Culture"/>
  <result pre="expression vector alone or the YFV CprME vector along with" exact="Zika" post="NS2B-3 expression plasmid. Culture supernatants were ultracentrifuged and analyzed"/>
  <result pre="the protease for cleavage and has been used previously for" exact="Zika" post="virus VLP production. We wanted to test whether JEV"/>
  <result pre="virus VLP production. We wanted to test whether JEV and" exact="YFV" post="CprME would be cleaved by the Zika NS2B3 protease."/>
  <result pre="whether JEV and YFV CprME would be cleaved by the" exact="Zika" post="NS2B3 protease. Cells were cotransfected with ZIKV NS2B3 with"/>
  <result pre="cleaved by the Zika NS2B3 protease. Cells were cotransfected with" exact="ZIKV" post="NS2B3 with either YFV or JEV CprME and the"/>
  <result pre="NS2B3 protease. Cells were cotransfected with ZIKV NS2B3 with either" exact="YFV" post="or JEV CprME and the supernatants were assayed for"/>
  <result pre="for VLP production. As demonstrated in Fig. 1B,D, JEV and" exact="YFV" post="constructs showed minimum VLP release into the supernatants in"/>
  <result pre="as detected by both E and CA antibodies. Moreover, both" exact="ZIKV" post="and WNV NS2B3 were efficient in cleaving ZIKV, YFV"/>
  <result pre="by both E and CA antibodies. Moreover, both ZIKV and" exact="WNV" post="NS2B3 were efficient in cleaving ZIKV, YFV and JEV"/>
  <result pre="both ZIKV and WNV NS2B3 were efficient in cleaving ZIKV," exact="YFV" post="and JEV CprME with comparable VLP release in the"/>
  <result pre="constructs show cellular expression of desired proteins and expression of" exact="Zika" post="NS2B3 with other flaviviral CprME can produce Capsid protein"/>
  <result pre="proteins (CprME) from a separate plasmid can complement a subgenomic" exact="WNV" post="replicon expressing a GFP reporter gene to generate RVPs."/>
  <result pre="has been shown to work well for different flaviviruses including" exact="WNV" post="and Zika13,21. We generated RVPs expressing JEV and YFV"/>
  <result pre="including WNV and Zika13,21. We generated RVPs expressing JEV and" exact="YFV" post="and ZIKV structural proteins and tested them for infectivity"/>
  <result pre="and Zika13,21. We generated RVPs expressing JEV and YFV and" exact="ZIKV" post="structural proteins and tested them for infectivity in Vero"/>
  <result pre="in Supplementary Figure 2A–C, Vero cells showed infection by JEV," exact="YFV" post="and ZIKV RVPs in a dose dependent manner. For"/>
  <result pre="Figure 2A–C, Vero cells showed infection by JEV, YFV and" exact="ZIKV" post="RVPs in a dose dependent manner. For CHIKV we"/>
  <result pre="YFV and ZIKV RVPs in a dose dependent manner. For" exact="CHIKV" post="we used a slightly different approach as it is"/>
  <result pre="Akahata et al.22, demonstrated that HIV reporter particles pseudotyped with" exact="CHIKV" post="Env generate a specific and sensitive RVP system that"/>
  <result pre="that can be used for neutralizing antibody detection. To develop" exact="CHIKV" post="RVPs, pcDNA3.1 vector expressing the Env region was co-transfected"/>
  <result pre="was co-transfected with HIV NL.LucR-E- vector to generate luciferase expressing" exact="CHIKV" post="pseudotyped RVPs. Once again, infection of Vero cells in"/>
  <result pre="of Vero cells in the presence of serial dilutions of" exact="CHIKV" post="RVPs showed a dose dependent luciferase signal (Supplementary Fig."/>
  <result pre="2D). Having developed RVP based infectivity assays for Zika, JEV," exact="YFV" post="and CHKV, we next asked if infection via RVPs"/>
  <result pre="a dose dependent manner. Moreover, no inhibition of JEV, YFV," exact="ZIKV" post="and CHIKV RVPs was seen in the presence of"/>
  <result pre="dependent manner. Moreover, no inhibition of JEV, YFV, ZIKV and" exact="CHIKV" post="RVPs was seen in the presence of matched control"/>
  <result pre="sera. Vero cells were infected with (A) JEV RVPs (B)" exact="YFV" post="RVPs (C) ZIKV RVPs or (D) CHIKV RVPs after"/>
  <result pre="were infected with (A) JEV RVPs (B) YFV RVPs (C)" exact="ZIKV" post="RVPs or (D) CHIKV RVPs after incubation with serial"/>
  <result pre="JEV RVPs (B) YFV RVPs (C) ZIKV RVPs or (D)" exact="CHIKV" post="RVPs after incubation with serial dilutions of virus specific"/>
  <result pre="mean ± SD of triplicate observations. Bicistronic vector expressing flaviviral CprME and" exact="Zika" post="NS2B3 produces Capsid protein containing VLPs The presence of"/>
  <result pre="immunogen and higher neutralizing antibody titers as seen in our" exact="Zika" post="VLP vaccine studies13,14. In order to produce CprME VLPs,"/>
  <result pre="lines. We have previously developed a biscistronic vector that co-expresses" exact="ZIKV" post="CprME and NS2B3 using an IRES sequence between the"/>
  <result pre="between the ORFs14. We used the same vector to replace" exact="Zika" post="CprME with either JEV or YFV CprME and tested"/>
  <result pre="same vector to replace Zika CprME with either JEV or" exact="YFV" post="CprME and tested them for VLP production. As demonstrated"/>
  <result pre="the bicistronic vectors resulted in robust production of JEV and" exact="YFV" post="VLPs in the supernatant that show incorporation of Capsid"/>
  <result pre="culture supernatants. Thus, a bicistronic vector expressing flaviviral CprME and" exact="Zika" post="NS2B3 robustly secretes Capsid protein containing VLPs into the"/>
  <result pre="lentiviral vector that included an IRES sequence followed by the" exact="Zika" post="NS2B-3 protease. 293 T cells were transfected with the JEV"/>
  <result pre="E protein and Capsid protein secretion via western blotting. (B)" exact="YFV" post="CprME was cloned into a lentiviral vector as above"/>
  <result pre="supernatants by western blotting for E and Capsid protein. (C)" exact="CHIKV" post="C-E3-E2-E1 genes were cloned into a lentiviral vector and"/>
  <result pre="Generation of stable cell lines producing ZIKV, YFV, JEV and" exact="CHIKV" post="VLPs Several successful VLP vaccines are currently in clinical"/>
  <result pre="up for commercial production. Using the bicistronic lentivirus vector expressing" exact="Zika" post="NS2B3 and flaviviral CprME’s, we generated stable cell lines"/>
  <result pre="generated stable cell lines that secrete high levels of JEV," exact="YFV" post="(Fig. 4A,B) and ZIKV VLPs14. For CHIKV, the lentivirus"/>
  <result pre="that secrete high levels of JEV, YFV (Fig. 4A,B) and" exact="ZIKV" post="VLPs14. For CHIKV, the lentivirus construct expressed the CE3E2E1"/>
  <result pre="by flow cytometry. Similarly, the YF9 clone was selected for" exact="YFV" post="(Fig. 4B) and CH3 clone for CHKV (Fig. 4C)"/>
  <result pre="CH3 clone for CHKV (Fig. 4C) for future analysis. The" exact="ZIKV" post="E2 cell line has been described and characterized before14."/>
  <result pre="find high VLP secreting single cell clones for JEV, YFV," exact="ZIKV" post="and CHIKV. These cell clones were used for VLP"/>
  <result pre="mice. Figure 4 Generation of stable cell lines secreting JEV," exact="YFV" post="and CHIKV VLPs. 293 T cells were transduced with (A)"/>
  <result pre="4 Generation of stable cell lines secreting JEV, YFV and" exact="CHIKV" post="VLPs. 293 T cells were transduced with (A) JEV (B)"/>
  <result pre="CHIKV VLPs. 293 T cells were transduced with (A) JEV (B)" exact="YFV" post="or (C) CHKV structural protein containing lentivirus particles. Transduced"/>
  <result pre="protein staining for the different single cell clones for JEV," exact="YFV" post="and CHIKV is shown on the right. Gel images"/>
  <result pre="for the different single cell clones for JEV, YFV and" exact="CHIKV" post="is shown on the right. Gel images were analyzed"/>
  <result pre="comparable VLP production for all four cell lines (JEV, CHIKV," exact="YFV" post="and ZIKV) as cells cultured in the presence of"/>
  <result pre="lines after long term culture. The morphology of JEV, CHIKV," exact="YFV" post="and ZIKV particles was consistent with that of virus"/>
  <result pre="long term culture. The morphology of JEV, CHIKV, YFV and" exact="ZIKV" post="particles was consistent with that of virus particles with"/>
  <result pre="with an average diameter of 40–50 nm or slightly larger for" exact="CHIKV" post="and densely staining membranes as demonstrated by electron microscopy"/>
  <result pre="combinations. We included a bivalent formulation that included JEV and" exact="CHIKV" post="VLPs as these two viruses are prevalent in Asia"/>
  <result pre="prevalent in Asia and a second bivalent group consisting of" exact="YFV" post="and CHIKV VLPs as these two viruses are endemic"/>
  <result pre="Asia and a second bivalent group consisting of YFV and" exact="CHIKV" post="VLPs as these two viruses are endemic in South"/>
  <result pre="EC50 values determined. Data for (A) JEV, (B) YFV, (C)" exact="ZIKV" post="and (D) CHIKV neutralization EC50 values from each mice"/>
  <result pre="Data for (A) JEV, (B) YFV, (C) ZIKV and (D)" exact="CHIKV" post="neutralization EC50 values from each mice are shown. All"/>
  <result pre="in immunized mice. For this, cell lysates form ZIKV, JEV," exact="YFV" post="and CHIKV VLP secreting stable cell lines were immunoprecipitated"/>
  <result pre="mice. For this, cell lysates form ZIKV, JEV, YFV and" exact="CHIKV" post="VLP secreting stable cell lines were immunoprecipitated with pooled"/>
  <result pre="Fig. 7A and consistent with the neutralizing antibody data, the" exact="CHIKV" post="monovalent VLP vaccine generated the strongest antibody titers followed"/>
  <result pre="combinations. This clearly demonstrates the presence of Capsid protein in" exact="CHIKV" post="VLPs and generation of an anti-Capsid immune response upon"/>
  <result pre="an anti-Capsid immune response upon immunization. For YFV, JEV and" exact="ZIKV" post="(Fig. 7B–D) again, specific E and prM antibodies were"/>
  <result pre="Overall, these data demonstrate the generation of specific YFV, JEV" exact="ZIKV" post="and CHIKV E, prM and Capsid antibodies upon immunization"/>
  <result pre="data demonstrate the generation of specific YFV, JEV ZIKV and" exact="CHIKV" post="E, prM and Capsid antibodies upon immunization with the"/>
  <result pre="cell lines for growth in suspension culture. (A) JEV, YFV," exact="ZIKV" post="and CHIKV stable cell lines were adapted to grow"/>
  <result pre="for growth in suspension culture. (A) JEV, YFV, ZIKV and" exact="CHIKV" post="stable cell lines were adapted to grow in suspension"/>
  <result pre="healthcare system25. The rise in arboviral outbreaks including CHIKV, JEV," exact="YFV" post="and more recently ZIKV is driven by multiple factors"/>
  <result pre="in arboviral outbreaks including CHIKV, JEV, YFV and more recently" exact="ZIKV" post="is driven by multiple factors including increased urbanization, increased"/>
  <result pre="an effective strategy in limiting outbreaks. Currently a JEV and" exact="YFV" post="vaccine is available in monovalent form29. Similarly a tetravalent"/>
  <result pre="is available in monovalent form29. Similarly a tetravalent vaccine for" exact="DENV" post="(DENV1-4) has recently been approved for use in individuals"/>
  <result pre="pregnant women. This is especially relevant in the case of" exact="ZIKV" post="vaccination where the target population is largely going to"/>
  <result pre="provides easy scale up and commercialization. A VLP vaccine against" exact="CHIKV" post="has shown efficacy in animal models and has now"/>
  <result pre="models and has now progressed to human trials22. Similarly a" exact="ZIKV" post="VLP vaccine has been tested in our lab in"/>
  <result pre="an additional antigen and better immunogenicity as evident from our" exact="Zika" post="studies13,14. Furthermore, previous studies on arboviral VLPs including CHIKV"/>
  <result pre="our Zika studies13,14. Furthermore, previous studies on arboviral VLPs including" exact="CHIKV" post="have been conducted in monovalent forms and there is"/>
  <result pre="towards determining whether a multivalent VLP formulation encompassing CHIKV, JEV," exact="YFV" post="and ZIKV would provide effective neutralizing response against all"/>
  <result pre="whether a multivalent VLP formulation encompassing CHIKV, JEV, YFV and" exact="ZIKV" post="would provide effective neutralizing response against all four viruses."/>
  <result pre="Virus (HPV) VLP vaccine is a 9 valent vaccine against" exact="HPV" post="types 6/11/16/18/31/33/45/52/58. Several studies have demonstrated the efficacy and"/>
  <result pre="group has developed a prME and CprME VLP vaccine against" exact="ZIKV" post="and demonstrated the superiority of Capsid protein containing VLP"/>
  <result pre="developed a strategy to generate Capsid protein containing VLPs for" exact="ZIKV" post="using a bicistronic vector that expresses the structural proteins"/>
  <result pre="that expresses the structural proteins CprME as well as the" exact="Zika" post="NS2B3 protease. This bicistronic vector helped us establish stable"/>
  <result pre="us establish stable cell lines that are high secretors of" exact="Zika" post="CprME VLPs14. In this study, we modified the bicistronic"/>
  <result pre="we modified the bicistronic vector by replacing CprME region of" exact="ZIKV" post="with that of YFV or JEV. Interestingly, ZIKV NS2B3"/>
  <result pre="vector by replacing CprME region of ZIKV with that of" exact="YFV" post="or JEV. Interestingly, ZIKV NS2B3 was effective at cleaving"/>
  <result pre="region of ZIKV with that of YFV or JEV. Interestingly," exact="ZIKV" post="NS2B3 was effective at cleaving C from prME for"/>
  <result pre="effective at cleaving C from prME for both JEV and" exact="YFV" post="allowing us to use the vector to establish stable"/>
  <result pre="Fisher) as per the manufacturer’s instructions. Antibodies for detection of" exact="Zika" post="Envelope (E) protein (GTX133314) and Capsid protein (GTX133317), JEV"/>
  <result pre="protein (GTX133317), JEV E protein (GTX125867) and Capsid protein (GTX634153)," exact="YFV" post="E protein (GTX134024) and Capsid protein (GTX134022) by western"/>
  <result pre="by western blotting were from GeneTex. For detection of ZIKV," exact="YFV" post="and JEV E protein by flow cytometry, the 4G2"/>
  <result pre="flow cytometry, the 4G2 antibody (MAB10216, Millipore) was used. For" exact="CHIKV" post="E1-E2 protein detection by flow cytometry and western blotting,"/>
  <result pre="blotting, the 6A11 clone was used from Novus Biologicals. JEV," exact="YFV" post="and ZIKV specific sera were kindly provided by BEI"/>
  <result pre="6A11 clone was used from Novus Biologicals. JEV, YFV and" exact="ZIKV" post="specific sera were kindly provided by BEI resources and"/>
  <result pre="specific sera were kindly provided by BEI resources and the" exact="CHIKV" post="specific sera was kindly provided by Centers for Disease"/>
  <result pre="was kindly provided by Centers for Disease Control. Plasmids The" exact="Zika" post="CprME vector has been described previously13. The WNV replicon"/>
  <result pre="Plasmids The Zika CprME vector has been described previously13. The" exact="WNV" post="replicon reporter plasmid Rep/GFP was kindly provided by Dr."/>
  <result pre="kindly provided by Dr. Ted Pierson (NIAID)21. Plasmid containing the" exact="WNV" post="NS2B3 accessory fusion protein expressing the active protease was"/>
  <result pre="was kindly provided by the AIDS reagent program. JEV and" exact="YFV" post="CprME regions were developed based on a consensus sequence"/>
  <result pre="synthetic genes were subcloned into pcDNA3.1+ expression vector. A codon optimized" exact="Zika" post="NS2B3 containing an HA Tag and IRES sequence was"/>
  <result pre="the lentiviral vector pLentiZikaCprME to generate pLentiZika CprME-IRES-NS2B314. To generate" exact="YFV" post="and JEV bicistronic constructs, the Zika CprME in the"/>
  <result pre="pLentiZika CprME-IRES-NS2B314. To generate YFV and JEV bicistronic constructs, the" exact="Zika" post="CprME in the pLentiZikaCprME vector was replaced with YFV"/>
  <result pre="the Zika CprME in the pLentiZikaCprME vector was replaced with" exact="YFV" post="and JEV CprME respectively. The NS2B-3 open reading frame"/>
  <result pre="to generate Zika-NS2B3. A similar approach was taken to generate" exact="CHIKV" post="structural protein (C-E3-E2-6K-E1) from a consensus sequence that was"/>
  <result pre="sequence that was further codon optimized and gene synthesized. The" exact="CHIKV" post="synthetic gene cassette was subcloned into pcDNA3.1+ vector as well"/>
  <result pre="subcloned into pcDNA3.1+ vector as well as pLenti6/V5 vector (Invitrogen). The" exact="CHIKV" post="E region (E3-E2-6K-E1) was PCR amplified from the synthetic"/>
  <result pre="construct and cloned into pCDNA3.1 TOPO vector to generate a" exact="CHIKV" post="E expression vector. Reporter virus particle assay Flaviviral Reporter"/>
  <result pre="generated as described previously13,35. Briefly, 239 T cells were transfected with" exact="WNV" post="Rep/GFP along with CprME plasmid from different flaviviruses (ZIKV,"/>
  <result pre="of GFP positive cells quantitated as described above. For the" exact="CHIKV" post="reporter virus assay, HIV reporter particles pseudotyped with CHIKV"/>
  <result pre="the CHIKV reporter virus assay, HIV reporter particles pseudotyped with" exact="CHIKV" post="E were used similar to the assay reported by"/>
  <result pre="the assay reported by Akahata et al.22. For this, the" exact="CHIKV" post="Envelope region (E3-E2-6K-E1) was PCR amplified from the synthetic"/>
  <result pre="and cloned into pCDNA 3.1 TOPO vector to generate a" exact="CHIKV" post="E expression vector. The HIV pNLLucR-E- vector that expresses"/>
  <result pre="minus the Env and includes a luciferase gene along with" exact="CHIKV" post="Env was used to generate luciferase expressing CHIKV pseudotyped"/>
  <result pre="along with CHIKV Env was used to generate luciferase expressing" exact="CHIKV" post="pseudotyped RVPs. Stable cell line generation Methods for the"/>
  <result pre="have been described previously13,14. Lentiviral vectors expressing ZIKV, JEV or" exact="YFV" post="CprME-IRES-NS2B-3 were packaged into lentiviral particles in 293 T cells"/>
  <result pre="Bulk selected cells were passaged 8–10 times and stained for" exact="ZIKV" post="E protein expression using monoclonal antibody MAB10216 (4G2, Millipore)"/>
  <result pre="further studies. The same strategy was used for generation of" exact="CHIKV" post="VLP secreting cell line. In this case the lentivirus"/>
  <result pre="secreting cell line. In this case the lentivirus expressed the" exact="CHIKV" post="structural proteins (C-E3-E2-6K-E1). The transduced 293 T cells were bulk"/>
  <result pre="cells were stained using E specific primary antibodies (4G2 or" exact="CHIKV" post="E Ab; 1:200 dilution) followed by Alexa 488 conjugated"/>
  <result pre="instructions. Cells were stained using the primary antibody 4G2 or" exact="CHIKV" post="E Ab at 1:500 dilution followed by secondary antibody"/>
  <result pre="and serum free media Stable cell lines secreting Zika, JEV," exact="YFV" post="and CHIKV VLPs were cultured in EX-CELL-293T serum free"/>
  <result pre="free media Stable cell lines secreting Zika, JEV, YFV and" exact="CHIKV" post="VLPs were cultured in EX-CELL-293T serum free media (Sigma)"/>
  <result pre="thank Dr. Ted Pierson (NIAID) for the sub-genomic GFP expressing" exact="WNV" post="replicon plasmids, Dr. Frank Scholle (NC State Univ.) for"/>
  <result pre="replicon plasmids, Dr. Frank Scholle (NC State Univ.) for the" exact="WNV" post="NS2B-3 protease plasmid, NIH AIDS Reagent Program for the"/>
  <result pre="Brandy Russell (CDC, Fort Collins, Colorado) for kindly providing the" exact="CHIKV" post="immune sera. We would also like to thank BEI"/>
  <result pre="would also like to thank BEI resources for the ZIKV," exact="YFV" post="and JEV immune sera and the TTUHSC-El Paso LARC"/>
  <result pre="Its Emergence in the Western HemisphereJournal of virology2016904864487510.1128/JVI.00252-1626962217 6.YactayoSStaplesJEMillotVCibrelusLRamon-PardoPEpidemiology of" exact="Chikungunya" post="in the AmericasThe Journal of infectious diseases2016214S441S44510.1093/infdis/jiw39027920170 7.SalimiHCainMDKleinRSEncephalitic Arboviruses:"/>
  <result pre="Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated" exact="Dengue" post="Vaccine (Dengvaxia): A Model Comparison StudyPLoS Med201613e100218110.1371/journal.pmed.100218127898668 12.WangJWRodenRBVirus-like particles"/>
  <result pre="Joshi, A. Development of Virus-Like-Particle Vaccine and Reporter Assay for" exact="Zika" post="Virus. Journal of virology91, 10.1128/JVI.00834-17 (2017). 14.GargHimanshuMehmetoglu-GurbuzTugbaRuddyGregory M.JoshiAnjaliCapsid containing"/>
  <result pre="10.1128/JVI.00834-17 (2017). 14.GargHimanshuMehmetoglu-GurbuzTugbaRuddyGregory M.JoshiAnjaliCapsid containing virus like particle vaccine against" exact="Zika" post="virus made from a stable cell lineVaccine201937487123713110.1016/j.vaccine.2019.09.09331607605 15.WongJasseyWangWangLiuLinVirus-Like Particle"/>
  <result pre="in the Flaviviridae FamilyVaccines20197412310.3390/vaccines7040123 16.PilsSJouraEAFrom the monovalent to the nine-valent" exact="HPV" post="vaccineClin Microbiol Infect20152182783310.1016/j.cmi.2015.05.00125980355 17.YamshchikovVFCompansRWFormation of the flavivirus envelope: role"/>
  <result pre="al.A rapid and quantitative assay for measuring antibody-mediated neutralization of" exact="West Nile" post="virus infectionVirology2006346536510.1016/j.virol.2005.10.03016325883 22.AkahataWet al.A virus-like particle vaccine for epidemic"/>
  <result pre="Nile virus infectionVirology2006346536510.1016/j.virol.2005.10.03016325883 22.AkahataWet al.A virus-like particle vaccine for epidemic" exact="Chikungunya" post="virus protects nonhuman primates against infectionNature medicine20101633433810.1038/nm.210520111039 23.MohsenMOZhaLCabral-MirandaGBachmannMFMajor findings"/>
  <result pre="Change and the Arboviruses: Lessons from the Evolution of the" exact="Dengue" post="and Yellow Fever VirusesAnnu Rev Virol2016312514510.1146/annurev-virology-110615-03563027482902 27.CollinsMHMetzSWProgress and Works"/>
  <result pre="particles as immunogensTrends in microbiology20031143844410.1016/S0966-842X(03)00208-713678860 32.JouraEBautistaO&amp;amp; Luxembourg, A. A 9-Valent" exact="HPV" post="Vaccine in WomenN Engl J Med20153722568256910.1056/NEJMc150435926107058 33.JouraEAet al.A 9-valent"/>
  <result pre="HPV Vaccine in WomenN Engl J Med20153722568256910.1056/NEJMc150435926107058 33.JouraEAet al.A 9-valent" exact="HPV" post="vaccine against infection and intraepithelial neoplasia in womenN Engl"/>
  <result pre="GirlsPediatr Infect Dis J20153499299810.1097/INF.000000000000077326090572 35.GargHLeeRTTekNOMaurer-StrohSJoshiAIdentification of conserved motifs in the" exact="West Nile" post="virus envelope essential for particle secretionBMC Microbiol20131319710.1186/1471-2180-13-19724007503 36.BrienJDLazearHMDiamondMSPropagation, quantification,"/>
  <result pre="for particle secretionBMC Microbiol20131319710.1186/1471-2180-13-19724007503 36.BrienJDLazearHMDiamondMSPropagation, quantification, detection, and storage of" exact="West Nile" post="virusCurrent protocols in microbiology20133115D 13 1115D 13 1810.1002/9780471729259.mc15d03s31"/>
 </snippets>
</snippetsTree>
